IGC Pharma (IGC) investor relations material

Executive summary

• Lead drug candidate IGC-AD1 reached target enrollment of 146 patients in Phase 2 CALMA trial for agitation in Alzheimer's dementia; trial remains ongoing with limited over-enrollment and follow-up activities.

• Pipeline includes early-stage candidates (e.g., TGR-63) and proprietary AI platforms (MINT-AD, AHA) for Alzheimer's research and clinical support.

• Revenue primarily from life sciences segment, with focus shifting to clinical development and AI platform advancement.

Financial highlights

• Revenue for Q2 2026 was $265K, down 19% year-over-year; six-month revenue was $582K, down 12%.

• Net loss for Q2 2026 was $2.94M (vs. $1.60M prior year); six-month net loss was $5.34M (vs. $2.80M prior year).

• Gross margin declined to 18% from 47% year-over-year due to product mix and transition to third-party manufacturing.

• Cash and cash equivalents at June 30, 2026, were $331K, down from $900K at year-end 2025.

• Working capital deficit increased to $2.0M from $366K at December 31, 2025.

Outlook and guidance

• Management expects continued operating losses as clinical and research programs advance.

• Current cash, anticipated financing, and a $12M credit facility expected to support operations for at least 12 months, subject to renewal and market conditions.

• Focus remains on completing CALMA trial, advancing AI platforms, and seeking non-dilutive grants.